Table 3.
Patient, cancer, and chemotherapy characteristics
| All patients (n=357) | Gold standard (n=82) | FN Patients: neutropenia, primary position (n=54) | FN Patients: neutropenia, any position (n=71) | FN Patients: Neutropenia + Fever,Any Position (n=28) | FN Patients: neutropenia or fever, any position (n=78) | FN Patients: neutropenia, fever, or infection, any position (n=201) | |
|---|---|---|---|---|---|---|---|
| Patient |
|
|
|||||
| Age (years), mean±SD |
64.2±13.0 |
62.1±13.8 |
63.3±15.1 |
62.6±14.8 |
61.3±16.3 |
63.0±14.5 |
65.5±12.3 |
| Male, % |
56.0 |
51.2 |
42.6 |
40.9 |
39.3 |
44.9 |
56.2 |
| Body Mass Index (kg/m2), mean±SD |
27.3±5.9 |
27.8±4.5 |
27.8±4.7 |
28.1±4.7 |
28.1±5.7 |
28.2±5.1 |
27.3±5.2 |
| N |
332 |
77 |
51 |
67 |
28 |
74 |
192 |
| Absolute Neutrophil Count (cells/L), mean±SD |
4.4±5.6 |
0.2±0.3 |
0.3±0.9 |
0.9±3.3 |
0.2±0.2 |
1.1±3.5 |
4.4±6.3 |
| N |
357 |
82 |
54 |
71 |
28 |
78 |
201 |
| Cancer |
|
|
|
|
|
|
|
| Type % |
|
|
|
|
|
|
|
| Bone, Connective Tissue, Skin, Breast | |||||||
| Female Breast |
9.8 |
19.5 |
18.5 |
18.3 |
28.6 |
17.9 |
11.9 |
| Other |
2.8 |
1.2 |
1.9 |
2.8 |
3.6 |
2.6 |
2.5 |
| Respiratory and Intrathoracic Organs | |||||||
| Trachea, Bronchus, Lung |
19.3 |
17.1 |
9.3 |
9.9 |
14.3 |
10.3 |
20.9 |
| Other |
1.4 |
2.4 |
5.6 |
4.2 |
3.6 |
3.8 |
2.0 |
| Digestive Organs and Peritoneum | |||||||
| Colon/Rectum |
10.9 |
9.8 |
5.6 |
5.6 |
7.1 |
5.1 |
9.5 |
| Pancreas |
7.8 |
1.2 |
1.9 |
2.8 |
0.0 |
5.1 |
7.0 |
| Esophagus |
2.5 |
2.4 |
0.0 |
0.0 |
0.0 |
0.0 |
1.0 |
| Other |
3.1 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
2.0 |
| Non-Hodgkin's Lymphoma |
11.2 |
20.7 |
25.9 |
23.9 |
28.6 |
24.4 |
14.9 |
| Genitourinary Organs | |||||||
| Bladder |
4.2 |
3.7 |
3.7 |
4.2 |
0.0 |
3.8 |
5.0 |
| Ovarian |
3.6 |
1.2 |
5.6 |
4.2 |
0.0 |
3.8 |
3.0 |
| Prostate |
2.8 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
3.0 |
| Uterus |
1.7 |
0.0 |
0.0 |
1.4 |
0.0 |
1.3 |
0.5 |
| Other |
2.8 |
1.2 |
1.9 |
1.4 |
0.0 |
1.3 |
2.0 |
| Lip, Oral Cavity, and Pharnyx |
2.0 |
1.2 |
0.0 |
0.0 |
0.0 |
0.0 |
1.5 |
| Blood Cancers |
6.7 |
13.4 |
13.0 |
14.1 |
14.3 |
14.1 |
8.0 |
| Hodgkin’s Lymphoma |
1.7 |
1.2 |
1.9 |
1.4 |
0.0 |
1.3 |
0.5 |
| Other |
5.6 |
3.7 |
5.6 |
5.6 |
0.0 |
5.1 |
5.0 |
| Presence of Metastases, % |
35.0 |
24.4 |
22.2 |
21.1 |
17.9 |
20.5 |
26.4 |
| Chemotherapy | |||||||
| No. of Myelosuppressive Drugs in Cycle 1, % | |||||||
| 1 |
32.2 |
20.6 |
26.1 |
27.4 |
38.1 |
29.4 |
29.2 |
| 2 |
47.2 |
50.7 |
45.7 |
46.8 |
38.1 |
44.1 |
49.7 |
| ≥3 |
20.6 |
28.8 |
28.3 |
25.8 |
23.8 |
26.5 |
21.1 |
| Year of Initiation, % |
|
|
|
|
|
|
|
| 2004-2005 |
41.7 |
37.8 |
42.6 |
42.3 |
14.3 |
39.7 |
37.3 |
| 2006-2007 |
28.3 |
28.1 |
22.2 |
23.9 |
32.1 |
23.1 |
31.4 |
| 2008-2010 | 30.0 | 34.2 | 35.2 | 33.8 | 53.6 | 37.2 | 31.3 |